Overview

Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions

Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
To asses bio equivalence between two (500 mg sulfadoxine / 25 mg pyrimethamine) formulation
Phase:
Phase 1
Details
Lead Sponsor:
Emzor Pharmaceutical Industries Limited
Treatments:
Pyrimethamine
Sulfadoxine